Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Universe PharmaceuticalsUPC -10.90%59 EV-to-OCF is 1.34 as of Aug. 10, 2026, which is 58% below its 10-year median of 3.21. GuruFocus rates UPC with a GF Score™ of 59/100 and a GF Value™ of $2.80 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Universe Pharmaceuticals ranks better than 69.28% on this metric.
The historical rank and industry rank for Universe Pharmaceuticals's EV-to-OCF or its related term are showing as below:
UPC'
s EV-to-OCF Range Over the Past 10 Years
Min: -17.4 Med: 3.21 Max: 17.33
Current: 1.34
During the past 8 years, the highest EV-to-OCF of Universe Pharmaceuticals was 17.33. The lowest was -17.40. And the median was 3.21.
UPC's EV-to-OCF is ranked better than 69.28% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 11.1
vs UPC: 1.34
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Universe Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Universe Pharmaceuticals's share price for today is $5.54.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Universe Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.380.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Universe Pharmaceuticals EV-to-OCF Related Terms
Universe Pharmaceuticals EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Universe Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Universe Pharmaceuticals EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Universe Pharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Universe Pharmaceuticals's EV-to-OCF falls into.
Universe Pharmaceuticals's current Enterprise Value is $-15.91 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Universe Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-11.91 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Universe Pharmaceuticals (UPC) has a EV-to-OCF of 1.34 as of Aug. 10, 2026. This is 58% below median its historical median of 3.21. According to the industry distribution chart, Universe Pharmaceuticals ranks #309 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 30.7%.
Is Universe Pharmaceuticals' EV-to-OCF too high?
Universe Pharmaceuticals' current EV-to-OCF of 1.34 is 58% below median its 10-year median of 3.21. The Drug Manufacturers industry median EV-to-OCF is 11.10. Universe Pharmaceuticals' value of 1.34 is 87.9% below this industry median. Based on the distribution chart, Universe Pharmaceuticals ranks #309 out of 1006 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Universe Pharmaceuticals has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Universe Pharmaceuticals' EV-to-OCF compare to NPHC and CBIH?
According to the Drug Manufacturers industry distribution chart, Universe Pharmaceuticals ranks #309 out of 1006 companies for EV-to-OCF. This puts Universe Pharmaceuticals in the upper half of its industry. The industry median EV-to-OCF is 11.10. Universe Pharmaceuticals' value of 1.34 is 87.9% below this benchmark. While the company's 10-year median is 3.21 vs. the industry median of 11.10, Universe Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 11.10, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Universe Pharmaceuticals's current EV-to-OCF of 1.34 is 87.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 11.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Universe Pharmaceuticals's current EV-to-OCF is 1.34, which is 58% below median its own 10-year median of 3.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Universe Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Universe Pharmaceuticals (UPC) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.80, compared to a current price of $5.54 — trading 97.9% above its estimated fair value. The current EV-to-OCF is 1.34, which is 58% below median its 10-year median of 3.21 and 87.9% below the Drug Manufacturers industry median of 11.10. Universe Pharmaceuticals' overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Universe Pharmaceuticals (UPC), the current EV-to-OCF is 1.34 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Universe Pharmaceuticals (UPC) Overvalued in 2026?
Based on GuruFocus' analysis, Universe Pharmaceuticals stock appears to be overvalued.
The current stock price of $5.54 is trading 97.9% above its estimated GF Value™ of $2.80.
GuruFocus considers Universe Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for UPC:
EV-to-OCF: 1.34 (58% below median its 10-year median of 3.21)
GF Value™: $2.80 vs. price of $5.54 (97.9% above fair value)
Industry Position: 87.9% below the Drug Manufacturers median (#309 of 1006)
No single metric tells the full story. See the UPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.
59GF Score
Get the complete analysis for UPC
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UPC has been successfully added to your 
